Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the
Nomination Committee’s proposal for a new Board of Directors that will be
submitted to the 2016 Annual General Meeting. The 2015-2016 Nomination Committee
comprises representatives of the company’s three largest shareholders at the end
of the third quarter of 2015 who have accepted a seat on the Nomination
Committee, and the Chairman of the Board. The composition of the 2015-2016
Nomination Committee was as follows: · Maria Rengefors, Chairman of the Nomination Committee, representing Nordea
Fonder · Anders Hallberg, representing HealthInvest Partners AB · Bo Öberg, representing the class A shareholders · Birgitta Stymne Göransson, Chairman of the Board of Medivir AB
The Nomination Committee has agreed, ahead of the upcoming 2016 Annual General
Meeting, to propose that a new Board of Directors be appointed by means of the
re-election of the Board’s existing Members, namely Anders Ekblom, Anders
Hallberg, Johan Harmenberg, Helena Levander and Anna Malm Bernsten, and the new
election of one Member, namely Thomas Axelsson. The Committee also proposes the
election of Anna Malm Bernsten as Chairman of the Board.
Bertil Samuelsson and Birgitta Stymne Göransson have declined re-election.
Thomas Axelsson, born 1959. Thomas has studied industrial engineering at
Linköping Technical Institute and is CEO of Vitrolife AB since 2011. He is a
also Member of the Board of MedCap AB. Thomas is a former CEO of Stille AB and
Artema AB and has worked for a number of companies in the life sciences and
medical technology sectors, including as a Business Area Manager at Baxter. He
has also been on the Board of several Life science companies including Chairman
of the Boards of SBL Vaccin AB, Neoventa Medical AB, Stille AB and Airsonett AB.
For more information please contact:
Maria Rengefors, Nordea Fonder, +46 10-1565 674.
Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 9.00 CET on 3 March 2016.
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.